Affirm Holdings Valuation
Is AFRM * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AFRM * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AFRM *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AFRM *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AFRM *?
Other financial metrics that can be useful for relative valuation.
What is AFRM *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$9.86b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 7.5x |
Enterprise Value/EBITDA | -22.1x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does AFRM *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3.1x | ||
GENTERA * Gentera. de | 1.7x | 20.5% | Mex$43.4b |
WEX WEX | 3.4x | 7.5% | US$8.8b |
EDEN Edenred | 4.8x | 12.7% | €11.0b |
INVEX A INVEX Controladora. de | 2.6x | 17.6% | Mex$13.4b |
AFRM * Affirm Holdings | 5.5x | 16.6% | Mex$9.9b |
Price-To-Sales vs Peers: AFRM * is expensive based on its Price-To-Sales Ratio (5.5x) compared to the peer average (3.1x).
Price to Earnings Ratio vs Industry
How does AFRM *'s PE Ratio compare vs other companies in the South American Diversified Financial Industry?
Price-To-Sales vs Industry: AFRM * is expensive based on its Price-To-Sales Ratio (5.5x) compared to the South American Diversified Financial industry average (1.5x).
Price to Sales Ratio vs Fair Ratio
What is AFRM *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 5.5x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate AFRM *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$572.00 | Mex$641.29 +12.1% | 33.1% | Mex$1,104.62 | Mex$339.88 | n/a | 16 |
Apr ’25 | Mex$580.51 | Mex$635.95 +9.6% | 35.4% | Mex$1,084.64 | Mex$216.93 | n/a | 16 |
Mar ’25 | Mex$640.05 | Mex$654.27 +2.2% | 37.8% | Mex$1,111.38 | Mex$222.28 | n/a | 18 |
Feb ’25 | Mex$676.00 | Mex$538.20 -20.4% | 52.1% | Mex$1,120.35 | Mex$103.42 | n/a | 19 |
Jan ’25 | Mex$830.00 | Mex$488.52 -41.1% | 55.8% | Mex$1,107.10 | Mex$102.19 | n/a | 18 |
Dec ’24 | Mex$649.00 | Mex$381.30 -41.2% | 40.5% | Mex$705.08 | Mex$103.18 | n/a | 19 |
Nov ’24 | Mex$311.50 | Mex$292.37 -6.1% | 35.5% | Mex$505.50 | Mex$108.32 | n/a | 18 |
Oct ’24 | Mex$373.00 | Mex$272.11 -27.0% | 35.8% | Mex$426.84 | Mex$102.44 | n/a | 16 |
Sep ’24 | Mex$374.50 | Mex$266.81 -28.8% | 32.5% | Mex$427.28 | Mex$102.55 | n/a | 18 |
Aug ’24 | Mex$331.00 | Mex$247.89 -25.1% | 31.9% | Mex$405.65 | Mex$101.41 | n/a | 18 |
Jul ’24 | Mex$278.39 | Mex$240.47 -13.6% | 30.2% | Mex$412.23 | Mex$103.06 | n/a | 18 |
Jun ’24 | Mex$258.15 | Mex$232.59 -9.9% | 24.6% | Mex$296.32 | Mex$104.58 | n/a | 16 |
May ’24 | Mex$178.90 | Mex$246.22 +37.6% | 23.0% | Mex$323.64 | Mex$107.88 | Mex$572.00 | 17 |
Apr ’24 | Mex$209.90 | Mex$249.11 +18.7% | 22.4% | Mex$324.40 | Mex$108.13 | Mex$580.51 | 18 |
Mar ’24 | Mex$225.20 | Mex$266.90 +18.5% | 23.3% | Mex$373.15 | Mex$111.95 | Mex$640.05 | 19 |
Feb ’24 | Mex$334.00 | Mex$335.96 +0.6% | 45.4% | Mex$856.57 | Mex$111.73 | Mex$676.00 | 19 |
Jan ’24 | Mex$187.00 | Mex$368.91 +97.3% | 44.7% | Mex$903.66 | Mex$157.16 | Mex$830.00 | 19 |
Dec ’23 | Mex$275.00 | Mex$404.89 +47.2% | 44.6% | Mex$1,003.09 | Mex$192.90 | Mex$649.00 | 19 |
Nov ’23 | Mex$405.00 | Mex$586.12 +44.7% | 35.1% | Mex$1,045.15 | Mex$295.80 | Mex$311.50 | 18 |
Oct ’23 | Mex$379.96 | Mex$641.84 +68.9% | 34.6% | Mex$1,059.37 | Mex$299.82 | Mex$373.00 | 18 |
Sep ’23 | Mex$463.00 | Mex$681.99 +47.3% | 45.0% | Mex$1,602.06 | Mex$300.39 | Mex$374.50 | 18 |
Aug ’23 | Mex$555.00 | Mex$719.02 +29.6% | 46.2% | Mex$1,643.47 | Mex$308.15 | Mex$331.00 | 18 |
Jul ’23 | Mex$360.00 | Mex$748.62 +107.9% | 43.7% | Mex$1,610.47 | Mex$301.96 | Mex$278.39 | 16 |
Jun ’23 | Mex$490.00 | Mex$776.74 +58.5% | 40.0% | Mex$1,596.03 | Mex$299.26 | Mex$258.15 | 15 |
May ’23 | Mex$605.01 | Mex$1,300.61 +115.0% | 23.2% | Mex$1,733.18 | Mex$570.93 | Mex$178.90 | 14 |
Analyst Forecast: Target price is less than 20% higher than the current share price.